Multiple risk intervention in high-risk hypertensive patients: A 3-year ultrasound study of intima-media thickness and plaques in the carotid artery

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 3, 1996, Pages 462-470

  Suurküla, Madis ^a   Agewall, Stefan ^b   Fagerberg, Björn ^b   Wendelhag, Inger ^c   Wikstrand, John ^c  

^a Institute of Heart and Lung Diseases   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

atherosclerosis; hypertension; prevention; risk factors; ultrasound

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING;

EID: 0029995061     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.3.462     Document Type: Article

References (47)

1. Kannel WB. An overview of the risk factors for cardiovascular disease. In: Genest J, Koiw E, Kuchel O, eds. Hypertension: Physiopathology and Treatment. New York, NY: McGraw Hill Book Co; 1977.
2. Wilhelmsen L. Synergistic effects of risk factors. Clin Exp Hypertens. 1990;A12:845-863.
3. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis. 1986;29(suppl 1):99-118.
4. Samuelsson O, Wilhelmsen L, Elmfeidt D, Pennert K, Wedel H, Wikstrand J, Berglund G. Predictors of cardiovascular morbidity in treated hypertension: results from the Primary Preventive Trial in Göteborg, Sweden. J Hypertens. 1985;3:167-176.
5. Wikstrand J, Warnold I, Tuomilehto J, Olsson G, Barber HJ, Eliasson K, Elmfeidt D, Jastrup B, Karatzas NB, Leer J, Marchetta F, Ragnarsson J, Robitaille N-M, Valkova L, Wesseling H, Berglund G. Metoprolol versus thiazide diuretics in hypertension: morbidity results from the MAPHY study. Hypertension. 1991;17:579-588.
6. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med. 1993;153:154-183.
7. Hjermann I, Velve Byre K, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial in healthy men. Lancet. 1981;2:1303-1310.
8. Wilhelmsen L, Berglund G, Elmfeidt D, Tibblin G, Wedel H, Pennert K, Vedin A, Wilhelmsson C, Werkö L. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986;7:279-288.
9. World Health Organization European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancet. 1986;1:869-872.
10. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the multiple risk factor intervention trial: findings related to a priori hypotheses of the trial. JAMA. 1990;263:1795-1801.
11. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? Lancet. 1990;336:129-133.
12. Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA. Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. JAMA. 1991;266:1225-1229.
13. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, William PT, Johnstone IM, Champagne MA, Krauss RM, Farquhar JW. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
14. Suurküla M, Agewall S, Fagerberg B, Wendelhag I, Widgren B, Wikstrand J, on behalf of the Risk Intervention Study (RIS) Group. Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high-risk hypertensive patients. Arterioscler Thromb. 1994;14:1297-1304.
15. Agewall S, Fagerberg B, Samuelsson O, Persson B, Hedner T, Andersson OK, Wikstrand J, Berglund G, on behalf of the Risk Factor Intervention Study group. Multiple cardiovascular risk factor intervention in treated hypertensive men: what can be achieved? Nutr Metab Cardiovasc Dis. 1993;3:128-135.
16. WHO study group. Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1980. Technical Report Series, No. 646.
17. Agewall S, Samuelsson O, Andersson OK, Persson B, Wikstrand J, Fagerberg B. The efficacy of multiple risk factor intervention in treated hypertensive men, during long term follow-up. J Intern Med. 1994;236:651-659.
18. Beckman Suurküla M, Wikstrand J, Berglund G, Sivertsson R. Body weight is more important than family history of hypertension for left ventricular function. Hypertension. 1991;17:661-668.
19. Rose GA, Blackburn H. Cardiovascular Survey Methods. Geneva, Switzerland: World Health Organization; 1968. WHO Monography Series, No. 56.
20. Klose S, Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem Greiner Selective Analyzer (GSA-II). J Clin Chem Clin Biochem. 1978;15:121-130.
21. Wahlefeld AW. Triglycerides: determination after enzymatic hydrolysis. In: Bergmeyer HK, ed. Method of Enzymatic Analysis. 2nd English ed. New York, NY: Academic Press Inc; 1974:1831.
22. Wiklund O, Fager G, Craigh IH, Wilhelmsson CE, Vedin A, Olofsson S-O, Bondjers, G. Alphalipoprotein cholesterol in relation to acute myocardial infarction and its risk factors. Scand J Clin Lab Invest. 1980;40:239-248.
23. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
24. Wendelhag I, Gustavsson T, Suurküla M, Berglund G, Wikstrand J. Ultrasound measurement of wall thickness in the carotid artery: fundamental principles and description of a computerized analyzing system. Clin Physiol. 1991;11:565-577.
25. Wikstrand J, Wendelhag I. Quantitative ultrasonography of carotid and femoral arteries. In: Lanzer P, Rösch J, eds. Vascular Diagnostics. Heidelberg, Germany: Springer Verlag; 1994:129-138.
26. Taylor DC, Strandness DE. Carotid artery duplex scanning. J Clin Ultrasound. 1987;15:635-644.
27. Blankenhorn DH, Selzer RH, Crawford DW, Barth JD, Liu C-r, Liu C-h, Mack WJ, Alaupovic P. Beneficial effects of colestipolniacin therapy on the common carotid artery: 2- and 4-year reduction of intima-media thickness measured by ultrasound. Circulation. 1993;88:20-28.
28. Mack WJ, Selzer RH, Hodis HN, Erickson JK, Liu C-r, Liu C-h, Crawford DW, Blankenhorn DH. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke. 1993;24:1779-1783.
29. Furberg CD, Adams HP, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunninghake DB, Lefkowitz DS, Probstfield J, Riley WA, Young B. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
30. Grouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW, McGovern ME, Furberg CD. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
31. Hodis HN, Mack WJ, Pogoda JM, Alaupovic P, Hemphill LC, Blankenhorn DH. Effect of triglyceride-rich lipoproteins on progression of early atherosclerotic lesions as determined by coronary angiography in the Mevinolin (Lovastatin) Atherosclerosis Regression Study (MARS). J Am Coll Cardiol. 1993;21(suppl A):71A. Abstract.
32. Salonen R, Nyyssönen K, Porkkala E, Rummukainen J, Salonen JT. KAPS: the effect of pravastatin on atherosclerotic progression in carotid and femoral arteries. Circulation. 1994;90:I-27. Abstract.
33. Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia: a three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis. 1995;117:225-236. In press.
34. Wendelhag I, Wiklund O, Wikstrand J. Atherosclerotic changes in the femoral and carotid arteries in familial hypercholesterolemia: ultrasonographic assessment of intima-media thickness and plaque occurrence. Arterioscler Thromb. 1993;13:1404-1411.
35. MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
36. The Scandinavian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344;1383-1389.
37. Pearson T, Marx HJ. The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications. Am J Cardiol. 1993;72:1072-1073.
38. Gotto AM Jr. Lipid lowering, regression, and coronary events: a review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. Circulation. 1995;92:646-656.
39. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
40. McClellan K. Views and reviews: unexpected results from MIDAS in atherosclerosis. Inpharma. 1994;(932):4.
41. Higgins G. MIDAS revisited: perhaps atherosclerosis was not to blame. Inpharma. 1995;(971):3-4.
42. Wikstrand J, Wiklund O. Frontiers in cardiovascular science: quantitative measurements of atherosclerotic manifestations in humans. Arterioscler Thromb. 1992;12:114-119.
43. Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J. Carotid artery wall morphology and insulin sensitivity: an ultrasound study in men at high and low coronary risk. Stroke. 1995;26:956-960.
44. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care. 1990;13:631-654.
45. Salonen JT, Salonen R. Risk factors for carotid and femoral atherosclerosis in hypercholesterolaemic men. J Intern Med. 1994;236:561-566.
46. Sutton-Tyrrell K, Wolfson SK Jr, Kuller LH. Blood pressure treatment slows the progression of carotid stenosis in patients with isolated systolic hypertension. Stroke. 1994;25:44-50.
47. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis. 1990;81:33-40.